1. Home
  2. SST vs IOBT Comparison

SST vs IOBT Comparison

Compare SST & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$2.70

Market Cap

12.9M

ML Signal

HOLD

Logo IO Biotech Inc.

IOBT

IO Biotech Inc.

HOLD

Current Price

$0.04

Market Cap

12.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SST
IOBT
Founded
2013
2014
Country
United States
Denmark
Employees
250
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
12.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SST
IOBT
Price
$2.70
$0.04
Analyst Decision
Strong Buy
Hold
Analyst Count
1
4
Target Price
$10.00
$2.25
AVG Volume (30 Days)
2.1M
186.6M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.77
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.03
52 Week High
$11.30
$2.79

Technical Indicators

Market Signals
Indicator
SST
IOBT
Relative Strength Index (RSI) 41.99 25.94
Support Level $2.01 N/A
Resistance Level $4.84 $0.22
Average True Range (ATR) 0.52 0.02
MACD -0.17 -0.01
Stochastic Oscillator 1.94 15.92

Price Performance

Historical Comparison
SST
IOBT

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.

About IOBT IO Biotech Inc.

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Share on Social Networks: